BEGIN:VCALENDAR VERSION:2.0 PRODID:-//CERN//INDICO//EN BEGIN:VEVENT SUMMARY:Total-Body PET Kinetic Modeling and Parametric Imaging with EXPLOR ER DTSTART;VALUE=DATE-TIME:20211009T142000Z DTEND;VALUE=DATE-TIME:20211009T144000Z DTSTAMP;VALUE=DATE-TIME:20260815T033435Z UID:indico-contribution-14-304@indico.koza.if.uj.edu.pl DESCRIPTION:Speakers: Guobao Wang (University of California Davis)\nDepart ment of Radiology\, University of California Health\, Sacramento CA 95817\ , USA\n\nThe uEXPLORER total-body PET system provides a very high level of detection sensitivity and simultaneous coverage of the entire body for dy namic imaging. This brings several potential benefits for tracer kinetic m odeling and parametric imaging\, including more reliable estimation of tra cer kinetics for clinical use\, noninvasive derivation of blood input func tion\, and total-body parametric imaging of micro kinetic parameters. Alon g with its attractive properties\, total-body kinetic modeling also brings significant challenges\, such as the large scale of total-body dynamic PE T data and the need for organ and tissue appropriate input functions and k inetic models. In this talk\, I will discuss the potential benefits\, tech nical challenges\, and examples of ongoing research applications of total- body kinetic modeling and parametric imaging.\n\nhttps://indico.koza.if.uj .edu.pl/event/4/contributions/304/ LOCATION:Theranostics Center / on-line URL:https://indico.koza.if.uj.edu.pl/event/4/contributions/304/ END:VEVENT BEGIN:VEVENT SUMMARY:Theranostics in particle therapy DTSTART;VALUE=DATE-TIME:20211009T134000Z DTEND;VALUE=DATE-TIME:20211009T140000Z DTSTAMP;VALUE=DATE-TIME:20260815T033435Z UID:indico-contribution-14-286@indico.koza.if.uj.edu.pl DESCRIPTION:Speakers: Antoni Rucinski (Instytut Fizyki Jądrowej PAN)\nPar ticle therapies with protons\, helium or carbon ions are emerging treatmen ts enabling precise targeting of pathological cancer tissues due to invert ed depth-dose distribution (Bragg peak) offering improved dose conformity with respect to conventional radiotherapy by X-rays. In addition to their dosimetric advantages\, protons and heavier ions penetrating patient tissu e undergo scattering and nuclear interactions and produce secondary radiat ion of different type\, i.e.\, radioactive isotopes\, ions\, photons\, and neutrons at varying energies. The secondary radiation induced by primary ions\, which is not present in conventional X-ray therapy\, can be detecte d and used to image therapeutic dose in the patient and gain information a bout patient anatomy simultaneously with the radiation therapy. I will rev iew the ongoing research and development of imaging methods based on secon dary radiation induced by particle beams\, focusing on the underlying pote ntial of particle therapy to be considered as theranostic approach to radi ation therapy.\n\nhttps://indico.koza.if.uj.edu.pl/event/4/contributions/2 86/ LOCATION:Theranostics Center / on-line URL:https://indico.koza.if.uj.edu.pl/event/4/contributions/286/ END:VEVENT BEGIN:VEVENT SUMMARY:Cyclotron production of theranostic pair 43/44Sc - 47Sc on calcium targets DTSTART;VALUE=DATE-TIME:20211009T130000Z DTEND;VALUE=DATE-TIME:20211009T132000Z DTSTAMP;VALUE=DATE-TIME:20260815T033435Z UID:indico-contribution-14-243@indico.koza.if.uj.edu.pl DESCRIPTION:Speakers: Rafał Walczak (Institute of Nuclear Chemistry and T echnology)\nThe 43Sc (T1/2 = 3.89 h) and 44Sc (T1/2 = 3.92 h) are an idea l β+ emitter in PET diagnosis. Both radionuclides can be used as an alter native to 68Ga\, because 43/44Sc has a longer half-life and forms theranos tic pair with β- emitter 47Sc\, which is important in planning radionucli de therapy. However in comparison with 44Sc\, 43Sc has half-life and beta plus radiation similar to 44Sc\, moreover\, gamma-ray energy emission and intensity is much lower (372 keV\, 23%) than in the case of 44Sc (1157 ke V\, 99%) what is not negligible for the patient and medical personnel. On the other hand 47Sc as low energy β- emitter is an attractive candidate f or radioimmunotherapy. In our work\, we propose a new way for cyclotron pr oduction of 43Sc in 42Ca(d\,n)43Sc nuclear reaction and 47Sc by proton irr adiation of 48Ca target in 48Ca(p\,2n)47Sc and 48Ca(p\,d)47Ca→47Sc rea ction. \n\nIn the present work\, we used enriched 42CaCO3\, 44CaCO3 and 48 CaCO3 targets (Isoflex\, Russia). To manufacture the targets enriched 42Ca CO3\, 44CaCO3 and 48CaCO3 powder was pressed with graphite powder ( 10-25% )\, mounted to a water-cooled target holder and irradiated with a beam of proton or deuteron at different energies. The activity of the samples was measured with high-resolution γ-ray spectrometry. CaCO3 targets were diss olved in 1 M HCl and a microfiltration process after alkalization of targe t material solution was used to separate 43/44Sc from calcium target mater ials and for production of 47Sc generator. The obtained by deuteron irradi ation of 42Ca radionuclide of 43Sc and 44Ca radionuclide of 44Sc were radi onuclidaly pure. In the case of proton irradiation of 48Ca obtained produc t contained a mixture of radionuclides 47Sc\, 48Sc\, and 47Ca which is a 4 7Sc mother radionuclide. After irradiation with 60 MeV proton beam followe d by chemical separation of the Ca isotopes and waiting for the maximum gr owth of 47Sc by 5\,6 days\, 44 MBq/µAh of 47Sc can be eluted from the gen erator with no other contaminating scandium activity. After separation sol ution of 43/44/47Sc was loaded on cation exchange Dowex 50 resin for purif ication and change of environment. \n\nThe proposed methods allow obtainin g high activity of 43Sc\, 44Sc and 47Sc. Scandium isotopes were separated from the targets with the efficiency of more than 90% and eluted in the vo lume of 0.5 ml. The level of Ca2+ in 43/44Sc and 47Sc fractions is less th an 3 µg/ml. The recovery of the calcium target is nearly quantitative mak ing the proposed production process economically feasible.\n\nScandium rad ionuclides\, separated by our method\, have sufficient quality for labelin g of the biologically active molecules\, which has been confirmed by label ing bioconjugates of Trastuzumab\, anti-HER2 nanobody and DOTA-TATE. For D TPA-Trastuzumab\, DTPA-nanobody and DOTA-TATE efficiency of labeling was 9 9% and for DOTA-nanobody 60% (t=50ºC).\n\n \n\nThis work was carried out as a part of the projects nr. IAEA-RC-23299-RO\n\nhttps://indico.koza.if. uj.edu.pl/event/4/contributions/243/ LOCATION:Theranostics Center / on-line URL:https://indico.koza.if.uj.edu.pl/event/4/contributions/243/ END:VEVENT BEGIN:VEVENT SUMMARY:Characterization and research on a large axial field of view PET i n Bern DTSTART;VALUE=DATE-TIME:20211009T140000Z DTEND;VALUE=DATE-TIME:20211009T142000Z DTSTAMP;VALUE=DATE-TIME:20260815T033435Z UID:indico-contribution-14-237@indico.koza.if.uj.edu.pl DESCRIPTION:Speakers: Kuangyu Shi (Dept. Nuclear Medicine\, University of Bern)\nRecent advances in the large axial field of view (LAFOV) PET revolu tionize PET imaging to meet several clinical demands. This talk will chara cterize the performance of a LAFOV PET (Siemens Biograph Vision Quadra) in stalled in Bern. On the other side\, the increased complexity makes the e xploration of the potential of the new instrument more challenging. This t alk will share some developments of artificial intelligence (AI) in LAFOV PET in Bern from the perspectives of imaging optimization. It will also di scuss the potentials and challenges during the development of AI technolog y.\n\nhttps://indico.koza.if.uj.edu.pl/event/4/contributions/237/ LOCATION:Theranostics Center / on-line URL:https://indico.koza.if.uj.edu.pl/event/4/contributions/237/ END:VEVENT BEGIN:VEVENT SUMMARY:In vitro and in vivo studies of iron oxide nanoparticles toxicity with theranostic potential DTSTART;VALUE=DATE-TIME:20211009T132000Z DTEND;VALUE=DATE-TIME:20211009T134000Z DTSTAMP;VALUE=DATE-TIME:20260815T033435Z UID:indico-contribution-14-234@indico.koza.if.uj.edu.pl DESCRIPTION:Speakers: Joanna Chwiej (AGH University of Science and Technol ogy)\nAmong the new materials exhibiting theranostic potential are undoubt edly magnetic iron oxide nanoparticles (IONPs) [1]. Due to their size\, th ey can interact at the cellular and molecular level of biological systems. In turn\, their unique magnetic properties mean that they can be used as contrast agents in MRI and as carriers for targeted drug transport\, allow ing for simultaneous monitoring of pharmaceutical distribution. IONPs can also induce local hyperthermia in response to an external magnetic field a nd thus selectively destroy cancer cells [2-5].\nExtensive efforts are now underway to design IONPs with the desired physicochemical properties. How ever\, in order to translate these theranostic nanomaterials (NMs) into cl inical practice\, the research aiming at determination of the biocompatibi lity of IONPs and the safety of their use in humans are necessary. The tox icity studies of NMs are mainly carried out *in vitro* on cell lines and c ultures. *In vitro* experiments provide mechanistic information on the tox icity of NMs and\, in particular\, on their genotoxicity\, cytotoxicity\, the possibility of causing oxidative stress or the development of inflamma tory processes in cells. They are\, therefore\, a very important step in t he complex process of enhancing NMs biocompatibility and their biomedical potential [6]. However\, their results cannot be directly translated into *in vivo* models\, which are still crucial and mandatory before the first human studies [7-8].\nThe talk will present the results of own research de monstrating how the use of instrumental techniques\, including the methods of atomic and molecular spectroscopy\, can support the characterization o f the properties of IONPs and the assessment of their toxicity and therape utic potential *in vitro* and *in vivo* [9-12].\nReferences:\n[1] Zhu L\, Zhou Z\, Mao H\, Yang L (2017) Nanomedicine (Lond) 12:73-87. [2] Corot C\, Robert P\, Idée JM\, Port M (2006) Adv Drug Deliv Rev 58:1471-1504. [3] Pankhurst QA\, Connolly J\, Jones SK\, Dobson J (2003) J Phys D Appl Phys 36:167-181. [4] Dobson J (2006) Drug Dev Res 67:55-60. [5] Sun C\, Lee JS\ , Zhang M (2008) Adv Drug Deliv Rev 60:1252-1265. [6] Dhawan A and Sharma V (2010) Anal Bioanal Chem 398:589-605. [7] Steger-Hartmann T and Raschke M (2020) Curr Opin Toxicol 23-24: 6-10. [8] Nayak R\, Meerovich I\, Dash A K (2019) AAPS PharmSciTech 20:160. [9] Matusiak K\, Skoczen A\, Setkowicz Z\, Kubala-Kukus A\, Stabrawa I\, Ciarach M\, Janeczko K\, Jung A\, Chwiej J (2017) Nanotoxicology 11:1225-1236. [10] Skoczen A\, Matusiak K\, Setko wicz Z\, Kubala-Kukus A\, Stabrawa I\, Ciarach M\, Janeczko K\, Chwiej J ( 2018) Chem Res Toxicol 31:876-884. [11] Janik-Olchawa N\, Drozdz A\, Rysza wy D\, Pudełek M\, Planeta K\, Setkowicz Z\, Sniegocki M\, Zadło A\, Ost achowicz B\, Chwiej J (2020) Sci Rep 10:15447. [12] Drozdz A\, Matusiak K\ , Setkowicz Z\, Ciarach M\, Janeczko K\, Sandt C\, Borondics F\, Horak D\, Babic M\, Chwiej J (2020) Spectrochim Acta A Mol Biomol Spectrosc 236:118 355.\n\nhttps://indico.koza.if.uj.edu.pl/event/4/contributions/234/ LOCATION:Theranostics Center / on-line URL:https://indico.koza.if.uj.edu.pl/event/4/contributions/234/ END:VEVENT END:VCALENDAR